HYLORIS news, videos and press releases
For more news please use our advanced search feature.
HYLORIS - More news...
HYLORIS - More news...
- Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
- Hyloris to Report 2023 Full-Year Results on 14 March 2024
- Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures
- Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)
- Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)
- Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral Suspension (HY-029)
- Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome
- Hyloris Announces Out-Licensing of Atomoxetine Oral Liquid in Canada
- Hyloris Pharmaceuticals Reports 2023 Half-Year Results and provides Business Outlook
- Hyloris announces potential registration date for Maxigesic® IV in the US
- Hyloris announces submission of Maxigesic® IV packaging data requested by the US FDA
- Hyloris Announces Commercial Partnership for Maxigesic® IV in 9 European Countries
- Hyloris Pharmaceuticals expands its Pipeline with a Product Candidate for a Mineral Deficiency in the Blood (hypophosphatemia)
- Hyloris Provides Additional Information on U.S. FDA Review of NDA Application for the Registration of Maxigesic IV®
- US FDA seeks more information on Maxigesic IV® application
- Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute Myeloid Leukaemia and Small Cell Lung Cancer
- Pleco Therapeutics Announces €8.7m Strategic Partnership with Hyloris to Progress its Novel Plecoid™ Agent in Acute Myeloid Leukaemia and Small Cell Lung Cancer
- Hyloris Announces Start of Phase 2 Study of Miconazole-Domiphen Bromide Vaginal Cream in Vulvovaginal Candidiasis
- Hyloris Acquires Breakthrough, Patented Technology to Develop and Market Aspirin IV in the U.S. in Acute Coronary Syndrome
- Hyloris Expands Cardiovascular Pipeline with Breakthrough Extended-Release Milrinone Capsule in Late-Stage Heart Failure
- Hyloris Appoints Jean-Luc Vandebroek as Chief Financial Officer
- Hyloris Announces Further Extension of Maxigesic® IV Footprint
- Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead
- Hyloris to Report 2021 Half-Year Results on 4 August 2021
- Hyloris Announces Launch of Maxigesic® IV, a Novel Non-Opioid Pain Treatment, in Key European Markets
- Hyloris Announces Extension of Footprint of Maxigesic® IV into South America